{"id":"NCT04944290","sponsor":"Padagis LLC","briefTitle":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","officialTitle":"Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide/Brimonidine Ophthalmic Suspension 1% to SimbrinzaÂ® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-28","primaryCompletion":"2022-03-11","completion":"2022-06-21","firstPosted":"2021-06-29","resultsPosted":"2025-04-02","lastUpdate":"2025-04-02"},"enrollment":447,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Brinzolamide/brimonidine ophthalmic suspension","otherNames":[]},{"type":"DRUG","name":"Simbrinza 0.2%/1% Ophthalmic Suspension","otherNames":[]}],"arms":[{"label":"Perrigo active","type":"EXPERIMENTAL"},{"label":"Reference active","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.","primaryOutcome":{"measure":"Mean Change in Intra-ocular Pressure","timeFrame":"6 weeks","effectByArm":[{"arm":"Perrigo Active","deltaMin":-5.3,"sd":3.181},{"arm":"Reference Active","deltaMin":-5.16,"sd":3.03}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":221},"commonTop":["Vision blurred","Dysgeusia"]}}